Financial News · Live Terminal

Page 598 of 687

Morgan Stanley Adjusts eBay Price Target to $117 From $119, Maintains Overweight Rating

eBay (EBAY) has an average rating of Hold and mean price target of $102.36, according to analysts polled by FactSet.Price: $100.92, Change: $+0.63, Percent Change: +0.62%

$EBAY

Wire147d ago

Morgan Stanley Adjusts Halliburton Price Target to $42 From $40, Maintains Overweight Rating

Halliburton (HAL) has an average rating of overweight and mean price target of $42.33, according to analysts polled by FactSet.Price: $40.18, Change: $+0.04, Percent Change: +0.11%

$HAL

Wire147d ago

Morgan Stanley Adjusts LyondellBasell Industries Price Target to $77 From $52, Maintains Overweight Rating

LyondellBasell Industries (LYB) has an average rating of hold and mean price target of $75.56, according to analysts polled by FactSet.Price: $71.41, Change: $+0.39, Percent Change: +0.54%

$LYB

Wire147d ago

Morgan Stanley Trims Truist Financial Price Target to $62 From $63, Maintains Overweight Rating

Truist Financial (TFC) has an average rating of overweight and mean price target of $55.21, according to analysts polled by FactSet.Price: $51.39, Change: $+0.16, Percent Change: +0.30%

$TFC

Wire147d ago

Roku Adds NBCUniversal's Peacock to Premium Subscriptions

Roku (ROKU) said Tuesday that NBCUniversal's Peacock Premium Plus service is now available through its Premium Subscription offerings in the US.Roku customers can now directly subscribe to Peacock Premium Plus via their Roku account and access content from NBCUniversal via The Roku Channel, the company said.Roku customers can get Peacock Premium Plus on the channel in the US for $16.99 per month or $169.99 a year, according to the company.Price: $111.88, Change: $-2.50, Percent Change: -2.19%

$ROKU

Wire147d ago

Gitlab Deepens Anthropic Integration to Add Claude Models

Gitlab (GTLB) said Tuesday it has deepened its integration with Amazon (AMZN)-backed Anthropic's Claude models, enabling customers to access the latest capabilities within its existing governance, compliance and audit framework.The integration includes the newly released Claude 4.7 Opus via Alphabet's (GOOG, GOOGL) Google Cloud and Amazon Web Services' Bedrock. This setup allows organizations to route artificial intelligence workloads through their existing hyperscaler contracts and meet specific data residency requirements, Gitlab said.GitLab also said it has joined the Claude Marketplace, enabling customers to purchase GitLab credits using their existing Anthropic spending commitments.Price: $22.62, Change: $+1.17, Percent Change: +5.45%

$AMZN$GOOG$GOOGL$GTLB

Wire147d ago

Pfizer Reaches Three Settlements in Vyndamax Patent Infringement Suits

Pfizer (PFE) said Tuesday it entered into settlement agreements with three generic drug manufacturers regarding lawsuits filed in the US District Court for the District of Delaware for patent infringement related to Vyndamax, a cardiomyopathy transthyretin-mediated amyloidosis treatment.The settlements extend the drug's effective US patent expiry date to June 1, 2031, subject to the outcome of other litigation, the company said."Pfizer had previously anticipated a significant decline in U.S. revenues for Vyndamax beginning in 2029 upon patent expiry," Pfizer said. "As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031."Price: $26.65, Change: $-0.15, Percent Change: -0.54%

$PFE

Wire147d ago

RTX's Raytheon Delivers Second Satellite Sensor to Lockheed Martin Under US Space Force Program

RTX-owned (RTX) Raytheon said Tuesday it has delivered its second sensor to Lockheed Martin (LMT) for the US Space Force's satellite program.The satellites, which are part of the Next-Generation Overhead Persistent Infrared Geosynchronous Earth Orbit Block 0 satellite program, will provide enhanced missile warning and tracking to deal with space-based threats, Raytheon said.Financial terms of the contract were not disclosed.Price: $173.20, Change: $-0.18, Percent Change: -0.10%

$LMT$RTX

Wire147d ago

Market Chatter: Disney TV Licenses May Be Reviewed by FCC

Walt Disney's (DIS) broadcast licenses are moving toward a review by the Federal Communications Commission, Semafor reported Tuesday, citing people familiar with the matter.The FCC may choose not to trigger the early license review process, the sources said, but its chairman Brendan Carr has threatened Disney's licenses as recently as this month over diversity issues, according to the report.Disney and the FCC didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $101.27, Change: $-1.08, Percent Change: -1.06%

$DIS

Wire147d ago

Solid Biosciences Says SGT-003 Gets EU Orphan Drug Designation for Duchenne Muscular Dystrophy

Solid Biosciences (SLDB) said Tuesday the European Commission has granted orphan drug designation to its investigational therapy SGT-003 for Duchenne muscular dystrophy.This decision followed a positive recommendation from the European Medicines Agency's Committee for Orphan Medicinal Products, the company said.SGT-003 already has been granted fast track, orphan drug, and rare pediatric disease designations by the US Food and Drug Administration, the company said, adding that the therapy is currently being tested in two clinical trials aimed at supporting regulatory approval in different countries.Price: $7.54, Change: $+0.04, Percent Change: +0.47%

$SLDB

Wire147d ago

Pfizer Reaches Three Settlements in Vyndamax Patent Infringement Suits

$PFE

Wire147d ago

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

Protagonist Therapeutics (PTGX) exercised its right to opt out of the 50/50 US profit and loss sharing arrangement under its global license and collaboration agreement with Takeda Pharmaceutical (TAK) for rusfertide, Protagonist Therapeutics said Tuesday.As a result, Protagonist Therapeutics will be eligible to receive up to $400 million in opt-out payments.The company will also be entitled to a $75 million milestone payment upon rusfertide's approval in the US and up to $975 million in other milestone payments and tiered royalties on net sales, according to the statement.Takeda Pharmaceutical now holds exclusive development and commercialization rights to rusfertide in the US.Rusfertide is under FDA Priority Review in the US for the treatment of adult patients with polycythemia vera, Protagonist Therapeutics said.Price: $99.31, Change: $+0.84, Percent Change: +0.85%

$PTGX$TAK

Wire147d ago

Morgan Stanley Trims Price Target on U.S. Bancorp to $64 From $65, Maintains Equalweight Rating

U.S. Bancorp (USB) has an average rating of overweight and mean price target of $62.85, according to analysts polled by FactSet.Price: $56.37, Change: $+0.40, Percent Change: +0.71%

$USB

Wire147d ago

Infleqtion Wins $1 Million US Navy Contract

Infleqtion (INFQ) said Tuesday that it has received a $1 million US Navy contract to support its Quantum-Inspired Rapid Context machine learning software platform for radio frequency signal processing.The company said the program will support the development of advanced radio-frequency signal-processing capabilities, enhancing situational awareness in complex environments.Infleqtion shares were down over 4% in Tuesday trading.Price: $12.58, Change: $-0.72, Percent Change: -5.41%

$INFQ

Wire147d ago

Dynatrace Shareholder Starboard Discloses Substantial Investment, Urges Constructive Engagement

Dynatrace (DT) was delivered a letter outlining operational strategies to accelerate revenue growth and profitability, Starboard Value said Tuesday.Starboard has made a substantial investment in Dynatrace, according to the letter.The shares currently trade at a severe valuation discount compared to infrastructure peers despite a durable product platform, Starboard added.Dynatrace has an opportunity for value creation, Starboard said, adding that it looks forward to a continued constructive engagement the company's management and the board regarding the goal.Dynatrace didn't immediately reply to request for comment from.Shares of Dynatrace were up 3.2% in Tuesday trading.Price: $36.73, Change: $+1.12, Percent Change: +3.13%

$DT

Wire147d ago

SIM Acquisition Executes LOI With American Industrial for Business Combination

SIM Acquisition Corp. I (SIMA) said Tuesday it has executed a non-binding letter of intent with American Industrial Technologies for a proposed deSPAC business combination.Among other segments, American Industrial Technologies will operate Q1, a fully integrated platform spanning manufacturing, logistics, distribution, and connected device ecosystems.The parties agreed to a 45-day exclusivity period to conduct due diligence and negotiate a definitive business combination agreement, according to the company.Price: $10.78, Change: $+0.01, Percent Change: +0.09%

$SIMA

Wire147d ago

Morgan Stanley Adjusts Price Target on CF Industries to $135 From $95, Maintains Equalweight Rating

CF Industries (CF) has an average rating of hold and mean price target of $122.06, according to analysts polled by FactSet.Price: $123.37, Change: $-0.26, Percent Change: -0.21%

$CF

Wire147d ago

Morgan Stanley Adjusts Targa Resources Price Target to $327 From $298, Maintains Overweight Rating

Targa Resources (TRGP) has an average rating of overweight and mean price target of $264.95, according to analysts polled by FactSet.Price: $245.31, Change: $+4.02, Percent Change: +1.67%

$TRGP

Wire147d ago

Morgan Stanley Adjusts Gilead Sciences Price Target to $175 From $171, Maintains Overweight Rating

Gilead Sciences (GILD) has an average rating of overweight and mean price target of $161, according to analysts polled by FactSet.Price: $128.85, Change: $+1.10, Percent Change: +0.86%

$GILD

Wire147d ago

Morgan Stanley Adjusts Sempra Price Target to $104 From $105, Maintains Overweight Rating

$SRE

Showing 11941-11960 of 13724